Synonym
Minocycline hydrochloride dihydrate; Minocycline HCl dihydrate
IUPAC/Chemical Name
2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, monohydrochloride, dihydrate, (4S,4aS,5aR,12aS)-
InChi Key
GZAQVQPBWMPNJU-ZMKIAWMISA-N
InChi Code
InChI=1S/C23H27N3O7.ClH.2H2O/c1-25(2)12-5-6-13(27)15-10(12)7-9-8-11-17(26(3)4)19(29)16(22(24)32)21(31)23(11,33)20(30)14(9)18(15)28;;;/h5-6,9,11,17,27,29-30,33H,7-8H2,1-4H3,(H2,24,32);1H;2*1H2/t9-,11-,17-,23-;;;/m0.../s1
SMILES Code
O.O.Cl.CN(C)[C@H]1[C@@H]2C[C@@H]3Cc4c(ccc(O)c4C(=O)C3=C(O)[C@]2(O)C(=O)C(=C1O)C(=O)N)N(C)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
529.97
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD002086. doi: 10.1002/14651858.CD002086.pub2. PMID: 22895927; PMCID: PMC7017847.
2: Rosenblat JD, McIntyre RS. Efficacy and tolerability of minocycline for depression: A systematic review and meta-analysis of clinical trials. J Affect Disord. 2018 Feb;227:219-225. doi: 10.1016/j.jad.2017.10.042. Epub 2017 Oct 28. PMID: 29102836.
3: Jonas M, Cunha BA. Minocycline. Ther Drug Monit. 1982;4(2):137-45. PMID: 7048646.
4: Allen JC. Minocycline. Ann Intern Med. 1976 Oct;85(4):482-7. doi: 10.7326/0003-4819-85-4-482. PMID: 788583.
5: Minocycline foam (Amzeeq) for acne. Med Lett Drugs Ther. 2020 May 4;62(1597):68-70. PMID: 32555112.
6: Zheng W, Zhu XM, Zhang QE, Cheng G, Cai DB, He J, Ng CH, Ungvari GS, Peng XJ, Ning YP, Xiang YT. Adjunctive minocycline for major mental disorders: A systematic review. J Psychopharmacol. 2019 Oct;33(10):1215-1226. doi: 10.1177/0269881119858286. Epub 2019 Jul 11. PMID: 31294649.
7: Haghi-Aminjan H, Asghari MH, Goharbari MH, Abdollahi M. A systematic review on potential mechanisms of minocycline in kidney diseases. Pharmacol Rep. 2017 Aug;69(4):602-609. doi: 10.1016/j.pharep.2017.02.001. Epub 2017 Feb 8. PMID: 28500967.
8: Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res. 2009 Jan 23;196(2):168-79. doi: 10.1016/j.bbr.2008.09.040. Epub 2008 Oct 11. PMID: 18977395.
9: Nagarakanti S, Bishburg E. Is Minocycline an Antiviral Agent? A Review of Current Literature. Basic Clin Pharmacol Toxicol. 2016 Jan;118(1):4-8. doi: 10.1111/bcpt.12444. Epub 2015 Aug 2. PMID: 26177421.
10: Ochsendorf F. Minocycline in acne vulgaris: benefits and risks. Am J Clin Dermatol. 2010;11(5):327-41. doi: 10.2165/11319280-000000000-00000. PMID: 20642295.
